Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with haematological malignancies-Reference-Cited by-同舟云学术

Population pharmacokinetics and site of action exposures of veliparib with topotecan plus carboplatin in patients with haematological malignancies

Published:2017-03-19 Issue:8 Volume:83 Page:1688-1700
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Br J Clin Pharmacol

Author:

Mehrotra Shailly¹,Gopalakrishnan Mathangi¹,Gobburu Jogarao¹,Greer Jacqueline M.²,Piekarz Richard³,Karp Judith E.²⁴,Pratz Keith²⁴,Rudek Michelle A.²⁴⁵

Affiliation:

1. Center for Translational Medicine; University of Maryland; Baltimore Maryland

2. The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Baltimore Maryland

3. Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute; Bethesda Maryland

4. Department of Oncology; Johns Hopkins University; Baltimore Maryland

5. Department of Medicine, Division of Clinical Pharmacology; Johns Hopkins University; Baltimore Maryland

Funder

National Center for Advancing Translational Sciences

National Cancer Institute

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcp.13253/fullpdf

Reference36 articles.

1. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands;Southan;Nucl Acids Res,2016

2. The Concise Guide to PHARMACOLOGY 2015/16: Enzymes;Alexander;Br J Pharmacol,2015

3. The Concise Guide to PHARMACOLOGY 2015/16: Transporters;Alexander;Br J Pharmacol,2015

4. PARP inhibition: PARP1 and beyond;Rouleau;Nat Rev Cancer,2010

5. Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1;Schreiber;J Biol Chem,2002

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The MILK study: Investigating intergenerational transmission of low-calorie sweeteners in breast milk;Contemporary Clinical Trials Communications;2023-12

2. A Population Pharmacokinetic Meta‐Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients;The Journal of Clinical Pharmacology;2021-06-19

3. Exposure–response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients;Cancer Chemotherapy and Pharmacology;2019-08-29

4. Recent Advances in Use of Topoisomerase Inhibitors in Combination Cancer Therapy;Current Topics in Medicinal Chemistry;2019-06-20

5. Population pharmacokinetics and exposure–response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias;Cancer Chemotherapy and Pharmacology;2018-11-20